BioSpace News Archive

Study published in Nature shows J&J’s investigational SARS-CoV-2 vaccine elicits a strong immune response that protects against subsequent infection

Teleflex Incorporated announced that 200,000 patients have been treated with the minimally invasive UroLift® System for benign prostatic hyperplasia worldwide.

Mesoblast Limited, global leader in allogeneic cellular medicines for inflammatory diseases, provided an update on upcoming milestones for its lead product candidate remestemcel-L, and an activity report for the fourth quarter ended June 30, 2020.

Women receiving standard treatment in New York City for ovarian, uterine, and cervical cancers are not at increased risk of being hospitalized for or dying from COVID-19 due to their cancer, a new study shows.

Aurinia Pharmaceuticals Inc. announced that it will release its second quarter 2020 financial results on Tuesday, August 11, 2020, after the markets close.

Second Quarter Revenues of $567.0 million, down 13.1% versus Prior Year Period; down 12.0% on a Constant Currency Basis

Neptune Wellness Solutions Inc. (“Neptune” or the “Company”) (NASDAQ: NEPT) (TSX: NEPT), a diversified and fully integrated health and wellness company focused on natural, plant-based, sustainable and purpose-driven lifestyle brands, announced today that it will report its financial results for the fiscal 2021 first quar

- INO-4800 showed durable antibody and T cell responses in rhesus macaques for 4 months - INO-4800 is the only vaccine to demonstrate long-term protection in non-human primates challenged with SARS-CoV-2 virus 13 weeks from vaccination - Memory T and B cell responses resulted in reduced viral loads and faster viral clearance in macaques’ lungs and nasal passages - INO-4800 vaccination generated antibodies neutralizing both the earlier strain of virus as well as the

Conference Call Scheduled for August 6, 2020 at 5:30pm Eastern Time

PolarityTE, Inc. (Nasdaq: PTE) today announced the appointment of Jessica Shen, MD, MS to the Company’s Board of Directors. Dr. Shen brings extensive clinical development, medical, health economics, regulatory, and quality control experience to PolarityTE’s Board of Directors. Dr. Shen spent more than 15 years at Johnson & Johnson, where she was most recently Vice President of Clinical Development and Regulatory Affai